Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
37.76 USD | +1.44% | +19.93% | +96.24% |
06-03 | Neurogene's Gene Therapy For Rett Syndrome Picked For FDA Pilot Program | MT |
06-03 | Neurogene Inc. Announces NGN-401 Gene Therapy for Rett Syndrome Selected by FDA for Start Pilot Program | CI |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+96.24% | 483M | |
+46.31% | 56.65B | |
-6.46% | 39.44B | |
+39.19% | 39.03B | |
-6.65% | 26.86B | |
+12.80% | 26.75B | |
-21.26% | 19.03B | |
+0.92% | 12.28B | |
+24.43% | 12.26B | |
+27.23% | 12.04B |
- Stock Market
- Equities
- NGNE Stock
- News Neurogene Inc.
- Transcript : Neoleukin Therapeutics, Inc., 2020 Earnings Call, Mar 25, 2021